









© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of 
America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. 
Intractable COVID-19 and Prolonged SARS-CoV-2 Replication in a 
CAR-T-cell Therapy Recipient: A Case Study  
 
Matthew K. Hensley1, William G. Bain1,2, Jana Jacobs3, Sham Nambulli4,5, Urvi Parikh3, 
Anthony Cillo6,7, Brittany Staines3, Amy Heaps3, Michele D. Sobolewski3, Linda J. Rennick4,5, 
Bernard J.C. Macatangay3, Cynthia Klamar-Blain3, Georgios D. Kitsios1, Barbara Methé1, 
Ashwin Somasundaram6,8, Tullia Bruno6, Carly Cardello6, Feng Shan6, Creg Workman6, 
Prabir Ray1,6, Anuradha Ray1,6, Janet Lee1,9, Rahil Sethi10, William E Schwarzmann10, Mark 
S. Ladinsky11, Pamela J. Bjorkman11, Dario A. Vignali6, W. Paul Duprex4,5, Mounzer E. 
Agha8, John W. Mellors3, Kevin D. McCormick3, Alison Morris1, and Ghady Haidar3* 
 
1Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, 
University of Pittsburgh School of Medicine, Pittsburgh, PA, USA 
2Staff Physician, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA 
3Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of 
Medicine, Pittsburgh, PA, USA 
4Center for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, PA, 
USA 
5Department of Microbiology and Molecular Genetics, University of Pittsburgh School of 
Medicine, Pittsburgh, PA, USA 
6Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 
USA 
7Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA 
8Division of Hematology, Oncology, Department of Internal Medicine, UPMC, Pittsburgh, PA, 
USA 



















10Department of Biomedical Informatics, University of Pittsburgh School of Medicine, 
Pittsburgh, PA, USA 
11Division of Biology and Biological Engineering, California Institute of Technology, 
Pasadena, CA, USA 
 
*Correspondence: 
Ghady Haidar, MD 
Division of Infectious Diseases, University of Pittsburgh and UPMC 
3601 Fifth Ave, Falk Medical Building, Suite 5B 

























A CAR-T-cell recipient developed severe COVID-19, intractable RNAemia, and viral 
replication lasting >2 months. Pre-mortem endotracheal aspirate contained 2x1010 SARS-
CoV-2 RNA copies/mL and infectious virus. Deep sequencing revealed multiple sequence 
variants consistent with intra-host virus evolution. SARS-CoV-2 humoral and cell-mediated 
immunity were minimal. Prolonged transmission from immunosuppressed patients is 
possible. 
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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients 
with hematologic malignancies results in poor coronavirus disease 2019 (COVID-19)-related 
outcomes[1].  Chimeric antigen-modified T-cell therapy (CAR-T-cell) recipients are at risk for 
severe COVID-19 because of chronic B-cell aplasia and hypogammaglobulinemia due to 
“on-target/off-tumor” effects of CAR-T-cells[2], which occur when CAR-T-cells kill normal B-
cells that express the CAR-T-cell target antigen. Conditioning regimens for CAR-T-cell 
therapy can also cause lymphopenia and diminish B- and T-cell function. Although 
persistence of SARS-CoV-2 RNA in respiratory specimens is not thought to represent 
infectiousness[3, 4], it is possible that CAR-T-cell recipients can persistently shed infectious 
SARS-CoV-2. Similarly, SARS-CoV-2 RNAemia, which correlates with disease severity[5], is 
thought to be short-lived[6] but may be more protracted in immunosuppressed hosts. 
We present a case of prolonged SARS-CoV-2 infection in a patient with multiple 
myeloma who received CAR-T-cells targeting the B-cell maturation antigen (BCMA), which is 
universally expressed on malignant plasma cells and on some normal plasma cells and 
mature B-cells and is involved in plasma cell survival and B-cell differentiation into plasma 
cells[7-10]. We characterize viral persistence, intra-host viral evolution, and immune profiles 
from longitudinal samples and demonstrate that the patient experienced high-level SARS-
CoV-2 RNAemia for >2 months, viral diversification, and massive lung infection before 
succumbing to the infection.  
Case report: 
The patient was a 73-year-old male with treatment-refractory multiple myeloma. He 
had undergone an autologous hematopoietic cell transplant 2 years prior but developed 
recurrent disease and therefore underwent anti-BCMA CAR-T-cell therapy after 
fludarabine/cyclophosphamide lymphodepletion. Nasopharyngeal (NP) swab reverse 
transcriptase polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 was negative 17 
and 2 days before CAR-T-cell therapy. He received tocilizumab for cytokine release 



















discharged home in stable condition. Twelve days after discharge (and 25 days after the 
CAR-T-cell infusion), he was admitted to the intensive care unit (ICU) with two days of a 
productive cough, dyspnea, anorexia, and lightheadedness. Temperature was 37.1○C; 
oxygen saturation was 86% on room air. Laboratory evaluation showed a white blood cell 
(WBC) count of 3.5x109 cells/L (normal 3.8x109-10.6x109), with an absolute lymphocyte 
count (ALC) and absolute neutrophil count (ANC) of 0.7x109 cells/L (normal 0.8 x109-3.65 
x109) and 2.6x109 cells/L (normal 2.24 x109-7.68 x109), respectively. NP swab RT-PCR 
testing was positive for SARS-CoV-2 RNA (day 0); cycle thresholds were 20.1 and 21.5 for 
the nucleoprotein (N)1 and envelope (E) genes, respectively (Figure 1-I). Chest radiograph 
revealed bibasilar and mid-zone opacities. He received convalescent plasma (day 2) and 
remdesivir (days 5-10). During this hospitalization, he had escalating oxygen requirements, 
necessitating the use of non-invasive positive pressure ventilation (NIPPV) on day 5. He 
never required intubation, and his oxygen requirements gradually improved over the 
following week. On day 14, he no longer needed supplemental oxygen and was discharged 
in stable condition on day 17, with minimal residual dyspnea. Follow-up SARS-CoV-2 NP 
RT-PCR testing remained positive (days 15, 26, and 37). Cycle thresholds were unavailable.  
Forty-one days after being diagnosed with COVID-19, he was readmitted to the ICU 
with a one-week history of weakness and four days of progressively worsening dyspnea, a 
minimally productive cough, and diarrhea. During the 24 days between hospital discharge 
and readmission, he had not left his residence except for obtaining outpatient SARS-CoV-2 
PCR testing. Temperature was 36.9○C. Oxygen saturation was 81% on room air, and he was 
started on heated high-flow supplemental oxygen with improvement in his saturation to 97%. 
WBC count and ANC were normal, but ALC was 0.1x109 cells/L. Lymphocyte subset testing 
showed 0 CD19+ B-cells and 32 CD3+ T cells/mm3 (normal 856-2669/mm3). Chest 
computed tomography demonstrated bilateral ground glass opacities (Figure 1-I).  
Since the literature at the time of the patient’s presentation suggested that prolonged 
PCR positivity indicated the presence of non-infectious RNA[3, 4], he initially received no 



















infections, which included blood cultures (grew Escherichia coli that rapidly cleared with 
piperacillin-tazobactam), and negative tests for urine Legionella antigen, plasma PCR for 
adenovirus, cytomegalovirus, and Epstein Barr virus, serum for Aspergillus galactomannan 
and beta-D-glucan, non-SARS-CoV-2 respiratory virus PCR, and stool pathogen PCR. He 
required pressor support on day 50 for hypotension, and his respiratory status continued to 
worsen. He was intubated on day 55 and required mechanical ventilation with 80%-100% 
fraction of inspired oxygen for the remainder of his hospital stay. SARS-CoV-2 NP RT-PCR 
testing remained positive on day 55; cycle thresholds were 13.3 and 16 for the N1 and E 
genes, respectively. Bronchoalveolar lavage fluid from day 55 grew rare Klebsiella 
pneumoniae, which was not thought to be significantly contributing to his condition but was 
treated with meropenem, which did not improve his respiratory status.    
Because no etiology aside from COVID-19 could be identified, he received another 
course of convalescent plasma (day 58) and dexamethasone (days 63-74) (Figure 1-I). He 
was unable to receive additional remdesivir due to limited availability. Serum from days 45, 
56, and 71 was negative for SARS-CoV-2 IgG and IgA (Euroimmun assay[11]).  Despite 
myeloma biomarkers showing an excellent response to CAR-T-cell therapy, his family 
ultimately decided to focus on comfort measures because of non-resolving respiratory 
failure. The patient passed away on day 74 after COVID-19 diagnosis. 
Methods: 
The patient was enrolled in the University of Pittsburgh’s Acute Lung Injury Registry 
and Biospecimen Repository (IRB# PRO10110387). SARS-CoV-2 RNA quantification was 
performed using a sensitive (limit of detection 3 copies/reaction) quantitative RT-PCR (qRT-
PCR) assay on plasma (days 4, 9, 13, 16, 67, and 71), and in endotracheal aspirate (ETA) 
fluid from day 72. SARS-CoV-2 Spike-specific deep next-generation sequencing (NGS) was 
performed on plasma (days 4, 13, 67, and 72) and ETA fluid (day 72). Virus isolation from 
plasma (days 4, 65, and 71) and ETA fluid (day 72) was attempted on Vero E6 cells, 
followed by indirect immunofluorescence and dideoxy sequencing of the Spike (S) gene. 



















domain (RBD) using an indirect enzyme-linked immunosorbent assay (ELISA), competitive 
ELISA using human ACE2, and pseudovirus neutralization assays were performed with 
samples from days 4, 9, 13, 16, and 72. Plaque reduction neutralization assays on cultured 
SARS-CoV-2 (laboratory strain) were also performed (days 4, 65, and 71). To characterize 
T-cell and B-cell responses, single-cell RNAseq (sc-RNASeq) was performed on peripheral 
blood mononuclear cells (PBMC) isolated from blood obtained on days 4 and 9.  SARS-CoV-
2 S-specific T-cell responses were determined by flow cytometric quantification of T-cell 
frequencies with intracellular staining of interferon-gamma (IFN)γ and CD107a, following co-
culture with S-protein and nucleocapsid protein peptide pools. Assay details can be found in 
the Supplementary Materials. 
Results: 
SARS-CoV-2 RNA measurements: 
High levels of SARS-CoV-2 RNA were detected in all plasma samples (Figure 1-I). 
RNAemia was greatest on day 4 (126,792 copies/mL) and showed a >10-fold decrease by 
day 9 (8,100 copies/mL), after administration of convalescent plasma and remdesivir. 
RNAemia remained readily detected but <100,000 copies/ml on days 13 (11,508 copies/mL), 
16 (18,000 copies/mL), and 67 (14,720 copies/mL), then increased to 101,800 copies/mL at 
day 71 during administration of dexamethasone. Over 20 billion copies/ml of SARS-CoV-2 
RNA (2.78x1010 copies/mL) were detected by qRT-PCR in a serially diluted ETA sample 
from day 72.  
Next generation sequencing of SARS-CoV-2 S gene in longitudinal samples: 
Six different SARS-CoV-2 sequence variants were identified in longitudinal plasma 
and ETA fluid between days 4, 13, 67, and 72 (Figure 2 and supplementary methods). On 
day 4, plasma viral S sequences matched the SARS-CoV-2 GH clade (containing D614G) 
that was circulating in Pittsburgh at the time.  However, by day 13, while the patient was still 
in the hospital, additional mutations were detected, including a including a R190K and 
G1124D substitution, which were previously observed in 0.005% (N=9/189,163) and 0% 



















between days 13 and 67 demonstrated the emergence of several additional mutations, such 
as a Y144 deletion and a D215G substitution, which were later identified in the United 
Kingdom (UK) and South African variants, respectively, several months after the patient’s 
death [12, 13]. We also identified an N501T substitution on day 67, which was recently 
shown to enhance binding affinity to the ACE2 receptor[14]. Interestingly, a substitution at 
the same location (N501Y) is currently circulating in the UK and South Africa[12, 13]. Finally, 
mutations continued to emerge between days 67 and 72 (e.g., H146 deletion). The 
longitudinal emergence of multiple different and novel sequence variants is indicative of 
intra-host evolution of SARS-CoV-2. 
Viral isolation and dideoxy sequencing: 
Infectious SARS-CoV-2 was recovered from the day-72 ETA sample (Figure 1-II) 
with a titer of 1.125x106 plaque forming units (PFU)/mL. Numerous SARS-CoV-2 virions 
were detected by electron microscopy in the ETA sample (Figure 1-III). Dideoxy sequencing 
of the S-gene of cultured virus showed mutations consistent with those identified by NGS 
(e.g., D614G substitution, Y144 deletion, and H146 deletion). Viral isolation from plasma 
was unsuccessful despite the presence of SARS-CoV-2 RNA. 
Immune responses: 
Analysis of PBMCs (days 4 and 9) by immunophenotyping and scRNA-Seq 
demonstrated absence of B-cells and near total depletion of T-cells, consistent with 
lymphodepleting chemotherapy with fludarabine and cyclophosphamide (Supplementary 
figure 2B). scRNA-Seq profiling showed interferon-stimulated genes in the monocyte 
lineage suggestive of a viral infection. We evaluated SARS-CoV-2-specific T-cell responses 
from days 4 and 67. The day 4 sample contained too few live T-cells (<1%) to assess. The 
day 67 PBMC sample showed somewhat higher levels of live T-cells (9.2%), with 1.72% and 
0.79% of CD8+T cells expressing the cytotoxicity marker CD107a following stimulation with 
S protein and nucleocapsid peptide pools, respectively, suggesting that a small fraction of 



















However, the low number of events (<5000 per sample) acquired by flow cytometry prevents 
any conclusions from being drawn from these analyses. 
Despite the administration of convalescent plasma on days 2 and 58, no IgG 
antibody targeting the S-protein RBD was detected at any time point, nor was there any 
antibody that competed with human ACE2 binding to RBD, possibly because the 
convalescent plasma used had a low titer of SARS-CoV-2 antibody, or there was rapid 
clearance of antibody bound to very higher numbers of virions (Supplementary table 2). 
Additionally, SARS-CoV-2 plaque reduction neutralization assays showed no plaque 
reduction in the day 4 sample. However, pseudovirus assays showed ~50% inhibition at a 
1:10 dilution in the day 13 sample (Supplementary figure 1). After the second dose of 
convalescent plasma on day 58, samples from days 65 and 71 showed > 50% plaque 
reduction at a 1:16 dilution. Since IgG antibody against the S-protein RBD was not detected 
at any time point (days 4, 9, 13, 16, 45, 56, 71 and 72), the observed plaque reduction 
suggests low titers of neutralizing antibodies or other proteins directed to non-RBD regions 
of the S-protein in the patient’s plasma (Supplementary table 2).  
Discussion 
We report here sustained SARS-CoV-2 RNAemia for >2 months and intra-host viral 
evolution in a patient with COVID-19 and both B- and T-cell depletion as a result of the 
therapies he had received for multiple myeloma. The initial clinical improvement and >10-
fold reduction in plasma RNAemia (days 4-9) suggests a treatment response following 
convalescent plasma (day 2) and remdesivir (days 5-10). RNAemia was never completely 
suppressed, however, and we hypothesize that the absence of anti-SARS-CoV-2 humoral 
responses and the paucity of T-cell responses related to prior chemotherapy and anti-BCMA 
CAR-T-cells resulted in uncontrolled viral replication and overwhelming SARS-CoV-2 
pneumonia (1.125x106 PFU/mL and 2.78x1010 RNA copies/mL in ETA) that likely contributed 
to death. The detection of a distinct SARS-CoV-2 sequence variant on day 13 of the first 
hospitalization with 3 coding mutations (Figure 2) compared to the initial viral variant 



















host and against superinfection or reinfection. Several additional sequence variants including 
those with coding mutations and deletions in the S gene that have yet to be detected in 
SARS-CoV-2 in Pittsburgh as of January 2021 were identified on day 67. Furthermore, 
additional sequence variants rapidly developed in the span of 5 days between days 67 and 
72 while the patient was still in the hospital (Figure 2), further supporting continued intra-
host viral evolution, since reinfection with 5 distinct variants is highly improbable. Taken 
together, these findings provide insights into the potential duration of continued SARS-CoV-2 
replication and the plasticity of the SARS-CoV-2 S gene, as others have noted[15].  
RNAemia has been described in immunocompromised patients with non-SARS-CoV-
2 respiratory viruses. Respiratory syncytial virus (RSV) RNAemia developed in 30% of 
hematopoietic cell transplant recipients 2 days after onset of RSV pneumonia and was a 
predictor of mortality[16]. Emerging data suggest that SARS-CoV-2 RNAemia may be a 
marker of severity of COVID-19 pneumonia[5, 17], but sustained RNAemia for >2 months 
has not yet been described. We were unable to isolate replication-competent virus from 
plasma, which may be due to technical issues, or may suggest that RNAemia is not caused 
by the presence of virions in the plasma, but rather due to “spillover” of infected cells with 
SARS-CoV-2 RNA from the lung. The reduction in plasma RNAemia between days 4 and 9 
(after administration of convalescent plasma on day 2 and of remdesivir between days 5 and 
10) suggests that viral replication was inhibited by the therapies given. Unfortunately, 
measurement of plasma RNAemia is not readily available for clinical use in the Unites 
States, and it is not currently known whether suppression of SARS-CoV-2 RNAemia can 
improve clinical outcomes. The rebound of viremia back to 101,800 RNA copies/mL on day 
71 occurred in the setting of the administration of dexamethasone. Whether corticosteroids 
should be avoided in heavily immunosuppressed individuals in whom prolonged SARS-CoV-
2 replication is suspected warrants further study. Ultimately, randomized trials are needed to 
evaluate whether measurement of RNAemia should be used to determine clinical response 



















We isolated virus from respiratory samples collected 72 days after COVID-19 onset, 
demonstrating the potential for infectivity late into the clinical course. In a prior study of 
immunocompetent patients with mild COVID-19, virus isolation from samples obtained after 
8 days was unsuccessful[3].  Our findings suggest that certain severely immunosuppressed 
patients with COVID-19 may require isolation longer than the 20-day period currently 
proposed by the Centers for Disease Control[18]. Whether PCR cycle thresholds (which 
were consistently <25 in our patient) can be used to make decisions related to 
discontinuation of transmission-based precautions warrants further investigation. 
Importantly, replication-competent variants isolated in cell culture harbored deletions 
associated with increased transmissibility similar to what has now been identified in the UK 
months later[12]. These findings raise the possibility that the origin of the highly mutated UK 
and South African variants may have been persons with protracted infection. 
Humoral and cell-mediated immunity after COVID-19 appear to be necessary to 
control SARS-CoV-2 infection [19, 20]. In our patient, PBMC analysis confirmed B-cell 
aplasia, which is compatible with negative assay results for IgGs against the S-protein RBD, 
or IgAs/IgGs using a clinically-approved assay. IgGs against the S-protein IBD were absent 
at all time points (days 4, 9, 13, 16, 45, 56, 71, and 72) despite the fact that the patient 
received convalescent plasma on days 2 and 58 of illness. This finding suggests either low 
titer of antibodies in the convalescent plasma or rapid clearance of antibodies in the context 
of high viral burden. Interestingly, there was evidence of low-level viral neutralization on days 
65 and 71 (after the second dose of convalescent plasma) using live virus neutralization 
assays, which may suggest the presence of low titers of neutralizing antibodies directed to 
non-RBD regions of Spike or low titers of other antibodies in the convalescent plasma 
samples. scRNA-Seq profiling from days 4 and 9 showed upregulation of interferon-
stimulated genes in monocytes, suggesting the presence of innate antiviral immunity, which 
was unable to control the infection. SARS-CoV-2-specific T-cell response assays did show 
some evidence of T-cell activation late into the disease course, although the T-cell 



















about the patient’s T-cell responses. Overall, these findings support the hypothesis that the 
diminished T-cell responses and nearly absent B-cell responses led to uncontrolled SARS-
CoV-2 infection. 
In conclusion, our case highlights that immunocompromised patients with profound 
lymphocyte defects such as CAR-T-cell therapy recipients are at risk for prolonged SARS-
CoV-2 replication. Other patients with severe lymphocyte deficiencies, such as anti-CD20 
monoclonal antibody recipients, and hematopoietic cell or organ transplant recipients within 
the first few months of transplant, may also be at risk. Clinicians caring for such patients 
should be cautious not to attribute persistent detection of SARS-CoV-2 RNA from clinical 
samples of these patients to the presence of non-infectious virus and should consider 
revising their transmission-based precautions for these patients. Further work is needed to 
define the role of monitoring RNAemia in managing immunocompromised persons with 
COVID-19, the duration of infectivity in these patients, the importance of intra-host 
emergence of SARS-CoV-2 sequence variants in immune escape, and the immune 
phenotypes associated with recovery versus fatal infection. More effective antiviral agents to 
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Figure 1. I) Clinical timeline showing CAR-T-cell infusion (days -25 to 0), first hospital 
admission (days 0-17), home stay (days 18-41), and second hospital admission (days 
41-74). Day 0 denotes day of first positive nasopharyngeal (NP) swab PCR for SARS-CoV-2 
RNA. The top panel shows the clinical course and timeline, with results of clinical SARS-
CoV-2 NP swab RT-PCR testing and clinical IgG and IgA testing. The bottom graph shows 
serial plasma SARS-CoV-2 RNA quantification obtained using a research qRT-PCR assay, 
with viral quantification from endotracheal aspirate fluid using research assays (qRT-PCR 
and infectious viral titer). Inset shows a coronal view of a chest CT (computed tomography) 
from day 41. Green squares: convalescent plasma (CP); red squares: remdesivir; yellow 
squares: dexamethasone. II) Indirect immunofluorescence of SARS-CoV-2 (Green) 
isolated in Vero E6 cells (Red/Blue) from day 72 endotracheal aspirate sample. Green: 
antibody directed against SARS CoV-2 spike protein (Sinobiologicals). Blue: DNA 
counterstained with DAPI. Red: filamentous actin counterstained with phalloidin. A syncytium 
is shown in the inset (B) at higher magnification. Scale bars: 100 µm. III) Electron 
microscopy of endotracheal aspirate sample obtained on day 72. (A) Comparison of 
virus localization in a bronchial epithelial cell (top) and a transient secretory cell (bottom). 
Each image is shown as montaged 2D overviews of the whole cell in a 200 nm section (left), 
overlaid with colored dots to indicate positions of virions (center) and 3D tomographic 
reconstructions detailing virus populations within cytoplasmic compartments. (B) 2D 
overview of SARS-CoV-2–infected ciliated epithelial cell in a 200 nm semi-thick section. The 
apical side of the cell is characterized by numerous membrane-bound compartments that 
are filled with SARS-CoV-2 virions. (C) Montaged tomogram of the apical side of the cell 
shown in B; hundreds of virus particles are contained within smooth-walled cytoplasmic 
compartments. Inset in C: Detail of a single virion with spikes indicated by red dots. (D) 
Tomogram detail of a smooth-walled cytoplasmic compartment containing at least 30 SARS-
CoV-2 virions within the shown 15 nm thick volume. 
 
Figure 2. Mutations and deletions in the SARS-CoV-2 Spike gene identified in the 
patient’s samples compared to the SARS-CoV-2 GISAID GH Clade circulating in 
Pittsburgh. The full genome at the top shows the GH clade sequence. The enlarged S gene 
shows all the mutations identified in the patient’s samples compared with the GH clade. The 
sequence alignments in S compared to the GH clade are shown for each of the multiple (6) 
sequence variants (var) identified by deep next-generation sequencing (Illumina). All of the 
sequence variants were detected in plasma. Day 72 (*) shows the matching sequence 
variants identified in the endotracheal aspirate sample. The D614G substitution was found in 
all samples. 
# indicates mutations detected as mixed populations <100%, but >20%.  
E envelope; FP; fusion peptide; HR 1, heptad repeat 1; M, membrane; N, nucleocapsid; 
NTD, N-terminal domain; ORF, open reading frame; SP, signal peptide RBD receptor 
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